AM

Ambu A/SCSE Ambu Stock Report

Last reporting period 30 Jun, 2024

Updated 18 Sep, 2024

Last price

Market cap $B

4.984

Middle

Exchange

XCSE - Nasdaq Copenhagen A/S

AMBU B.CO Stock Analysis

AM

Neutral

Based on Eyestock quantitative analysis, AMBU B.CO`s fundamental data and valuation indicate an investment grade of Neutral at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

74/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

130.8 %

Greatly undervalued

Market cap $B

4.984

Dividend yield

0.17 %

Shares outstanding

223.4 B

Ambu A/S engages in the development, production, and marketing of diagnostic and life-supporting devices for hospitals and rescue services. The Company’s operations are structured into three business areas: Anaesthesia, Patient Monitoring & Diagnostics and Emergency Care. The Anaesthesia business area offers a range of products such as resuscitators, face masks and laryngeal masks. The Patient Monitoring & Diagnostics business area comprises single use electrodes for cardiological and neurological examinations. The target groups for these products are hospitals, clinics, ambulance services and sleep labs. The Emergency Care business area offers ventilation bags, neck collars and manikins for first-aid training. The firm markets its products worldwide. The firm operates King Systems Inc, First Water Heathcote Ltd and Invendo Medical GmbH as subsidiaries.

View Section: Eyestock Rating